Demir, Mehmet Emin

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/7115
Name Variants
Demir, M. E.
Mehmet Emin, Demir
Demir M.
Demir,M.E.
D.,Mehmet Emin
D., Mehmet Emin
M. E. Demir
M.E.Demir
Emin M.
Demir, Mehmet E.
M., Demir
Demir, Mehmet Emin
M.,Demir
Job Title
Doçent Doktor
Email Address
mehmet.demir@atilim.edu.tr
Main Affiliation
Internal Medical Sciences
Status
Website
ORCID ID
Scopus Author ID
57213282312
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
V-3453-2017

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
5
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
1
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

30

Citations

367

h-index

8

Go to Scopus profile
Documents

47

Citations

504

Go to WoS profile
Scholarly Output

11

Articles

10

Views / Downloads

3/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

25

Scopus Citation Count

22

Patents

0

Projects

0

WoS Citations per Publication

2.27

Scopus Citations per Publication

2.00

Open Access Source

10

Supervised Theses

0

JournalCount
Frontiers in Immunology2
Frontiers in Public Health1
Frontiers in Systems Neuroscience1
International Journal of General Medicine1
International Urology and Nephrology1
Current Page: 1 / 2

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

20253
Reset filters

Settings

Author: Cesur, SalihSubject: Hemodialysis

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Evaluation of Anti-Tetanus IgG Antibody Levels and Influencing Factors in Patients Undergoing Hemodialysis
    (Frontiers Media Sa, 2025) Ozsoy, Metin; Ozturk, Hakki; Tuna, Aysegul; Varlibas, Artuner; Cesur, Salih; Aksoy, Altan; Demir, Mehmet Emin
    Aim: This study aimed to assess anti-tetanus IgG antibody levels and identify determinants of inadequate tetanus immunity among maintenance hemodialysis (HD) patients. Methods: In this cross-sectional study, anti-tetanus IgG levels were measured by quantitative ELISA in 162 adult HD patients from two dialysis centers in Ankara, Turkey. Protective immunity was evaluated using both international (>= 0.1 IU/mL) and robust (>= 0.5 IU/mL) cut-offs. Demographic and clinical factors associated with immunity were analyzed by multivariate logistic regression. Results: Only 16.7% of HD patients achieved robust protection (>= 0.5 IU/mL), whereas 49.8% had minimal protection (>= 0.1 IU/mL). Protective immunity was independently associated with younger age (OR 1.07 per year; p = 0.004), shorter dialysis duration (OR 1.07; p = 0.030), male sex (female OR 2.92; p = 0.048), and recent booster vaccination within 10 years (OR 0.11; p < 0.001). Diabetes mellitus was not an independent factor. Conclusion: Most HD patients lacked durable tetanus immunity, particularly older females on long-term dialysis. The findings highlight the need for regular antibody monitoring, early revaccination, and structured booster programs to maintain adequate protection in this high-risk population.
  • Thumbnail Image
    Article
    Comparison of SARS-CoV IgG Responses in Hemodialysis Patients and Healthcare Workers After COVID-19 Vaccination
    (Frontiers Media S.A., 2025) Ozturk, Hakki; Ozsoy, Metin; Tuna, Aysegul; Varlibas, Artuner; Cesur, Salih; Aksoy, Altan; Demir, Mehmet Emin
    Aim: This study aimed to compare SARS-CoV-2 IgG antibody levels in hemodialysis (HD) patients and healthcare workers (HCWs) after COVID-19 vaccination and to identify factors influencing these levels. Materials and methods: A total of 193 participants were included: 104 HD patients and 89 age- and sex-matched HCWs as controls. All had completed a primary COVID-19 vaccination series (two doses of CoronaVac or BNT162b2) and a booster dose. SARS-CoV-2 anti-spike IgG was measured at least one month after the last vaccine dose using a commercial immunoassay (Abbott SARS-CoV-2 IgG II Quant, CMIA). Results in Arbitrary Units (AU/mL) were converted to WHO standard Binding Antibody Units (BAU/mL) (1 AU/mL = 0.142 BAU/mL). IgG titers >= 7.1 BAU/mL (equivalent to 50 AU/mL) were considered positive. Results: All participants had positive SARS-CoV-2 IgG antibodies. There were no statistically significant differences in IgG levels between HD patients and HCWs at any individual time interval (<3 months, 3-6 months, or >6 months) or in the overall mean titers (HD: 1259 +/- 1112 BAU/mL; HCW: 1002 +/- 765 BAU/mL; p = 0.216). No individual in either group had an IgG titer below 7.1 BAU/mL. Vaccine type, dialysis vintage, and presence of comorbidities did not significantly impact antibody levels. In the HCWs group, those vaccinated only with CoronaVac had significantly lower IgG levels than those receiving only BNT162b2 or a heterologous regimen (CoronaVac followed by BNT162b2). However, among HD patients, IgG levels did not differ by vaccine regimen. Conclusion: HD patients mounted a SARS-CoV-2 IgG antibody response comparable to that of healthy HCWs, with no participant falling below the positivity threshold. Dialysis duration and comorbid conditions did not significantly affect post-vaccination IgG levels. While HCWs who received only CoronaVac showed lower antibody titers than those who received BNT162b2 or a heterologous schedule, this difference was not observed in HD patients. These results suggest that COVID-19 vaccination elicits a robust humoral immune response in the HD population, underscoring the benefit of vaccination in this high-risk group.
  • Thumbnail Image
    Article
    Investigation of Hepatitis E Virus Seroprevalence and Risk Factors in Hemodialysis Patients
    (Frontiers Media Sa, 2025) Ozturk, Hakki; Ozsoy, Metin; Tuna, Aysegul; Varlibas, Artuner; Cesur, Salih; Aksoy, Altan; Demir, Mehmet Emin
    Background: Hemodialysis patients are at increased risk for hepatitis E virus (HEV) infection due to their immunocompromised status and frequent exposure to invasive medical procedures. HEV can lead to chronic infections and severe complications, particularly in high-risk populations. This study aimed to determine HEV-IgG seroprevalence among hemodialysis patients in Ankara, Turkey, and evaluate associated risk factors. Methods: A total of 160 hemodialysis patients from three private dialysis centers in Ankara were included in this prospective, cross-sectional study. Anti-HEV-IgG antibodies were detected using the ELISA method. Demographic characteristics and potential risk factors, including dialysis duration, comorbidities, blood transfusion history, drinking water source, dietary habits, and involvement in animal husbandry, were assessed via structured surveys. Statistical analyses were conducted using SPSS Version 22.0, with Pearson's chi-square and Fisher's exact tests applied to categorical variables. Logistic regression analysis was performed to identify independent risk factors for HEV seropositivity. Results: HEV-IgG seropositivity was detected in 42 patients (26.25%). Seroprevalence increased significantly with age, rising from 6.7% in patients under 55 years to 47.4% in those over 65 years (p < 0.001). Extended dialysis duration (>5 years) was also significantly associated with HEV seropositivity (p = 0.02). However, no significant associations were found between HEV seropositivity and gender, blood transfusion history, source of drinking water, consumption of raw meat, or involvement in animal husbandry (p > 0.05). Conclusion: The HEV-IgG seroprevalence among hemodialysis patients in Ankara was higher than previously reported rates in Turkey. Age and prolonged dialysis duration emerged as significant risk factors, underscoring the importance of screening and preventive strategies in this vulnerable population. Further multi-regional studies are needed to better understand HEV transmission dynamics and improve management strategies in hemodialysis patients.